CY1116734T1 - Παραγωγα κινολινης και κινοξαλινης ως αναστολεις της κινασης - Google Patents
Παραγωγα κινολινης και κινοξαλινης ως αναστολεις της κινασηςInfo
- Publication number
- CY1116734T1 CY1116734T1 CY20151100718T CY151100718T CY1116734T1 CY 1116734 T1 CY1116734 T1 CY 1116734T1 CY 20151100718 T CY20151100718 T CY 20151100718T CY 151100718 T CY151100718 T CY 151100718T CY 1116734 T1 CY1116734 T1 CY 1116734T1
- Authority
- CY
- Cyprus
- Prior art keywords
- autoimmune
- derivatives
- kinoxaline
- kinolin
- models
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Abstract
Μια σειρά παραγώγων κινολίνης και κινοξαλίνης, τα οποία έχουν μια φθοριωμένη πλευρική άλυσο αιθυλίου και είναι επιλεκτικοί αναστολείς των ενζύμων Ρ13 κινάσης, και ως εκ τούτου είναι επωφελείς ως φαρμακευτικοί παράγοντες, παραδείγματος χάριν στην θεραπεία των φλεγμονωδών, αυτοάνοσων καρδιαγγειακών, νευροεκφυλιστικών, μεταβολικών, ογκολογικών, αλγαισθητικών και οφθαλμικών παθήσεων.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1014963.1A GB201014963D0 (en) | 2010-09-08 | 2010-09-08 | Therapeutic agents |
| GBGB1101128.5A GB201101128D0 (en) | 2011-01-21 | 2011-01-21 | Therapeutic agents |
| EP20110755423 EP2614061B1 (en) | 2010-09-08 | 2011-09-02 | Quinoline and quinoxaline derivatives as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116734T1 true CY1116734T1 (el) | 2017-03-15 |
Family
ID=45810169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100718T CY1116734T1 (el) | 2010-09-08 | 2015-08-18 | Παραγωγα κινολινης και κινοξαλινης ως αναστολεις της κινασης |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9029392B2 (el) |
| EP (1) | EP2614061B1 (el) |
| JP (1) | JP5820882B2 (el) |
| KR (1) | KR101880280B1 (el) |
| CN (1) | CN103153996B (el) |
| AR (1) | AR082799A1 (el) |
| AU (1) | AU2011300521B2 (el) |
| BR (1) | BR112013004750B1 (el) |
| CA (1) | CA2808959C (el) |
| CL (1) | CL2013000603A1 (el) |
| CO (1) | CO6680717A2 (el) |
| CY (1) | CY1116734T1 (el) |
| DK (1) | DK2614061T3 (el) |
| EA (1) | EA024162B1 (el) |
| ES (1) | ES2544289T3 (el) |
| HK (1) | HK1181754A1 (el) |
| HR (1) | HRP20150868T1 (el) |
| HU (1) | HUE025223T2 (el) |
| IL (1) | IL224841A (el) |
| MA (1) | MA34600B1 (el) |
| ME (1) | ME02203B (el) |
| MX (1) | MX2013002529A (el) |
| MY (1) | MY162396A (el) |
| NZ (1) | NZ607966A (el) |
| PL (1) | PL2614061T3 (el) |
| PT (1) | PT2614061E (el) |
| RS (1) | RS54202B1 (el) |
| SG (1) | SG187924A1 (el) |
| SI (1) | SI2614061T1 (el) |
| SM (1) | SMT201500195B (el) |
| TW (1) | TWI510489B (el) |
| WO (1) | WO2012032334A1 (el) |
| ZA (1) | ZA201301751B (el) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| TWI565709B (zh) | 2011-07-19 | 2017-01-11 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
| CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| CN109776525B (zh) | 2013-04-19 | 2022-01-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
| ES2900806T3 (es) | 2013-10-04 | 2022-03-18 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN104744435B (zh) * | 2013-12-25 | 2017-03-01 | 上海医药工业研究院 | 喹啉类化合物、其盐、其中间体、制备方法及应用 |
| JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物 |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
| US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| GB201608797D0 (en) * | 2016-05-19 | 2016-07-06 | Ucb Biopharma Sprl | Therapeutic use |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN108239076B (zh) * | 2016-12-26 | 2021-07-06 | 中国医学科学院药物研究所 | 喹唑啉类化合物及其制备方法、用途和药物组合物 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| GB201708856D0 (en) * | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2139882B1 (en) | 2007-03-23 | 2013-12-25 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| WO2008118454A2 (en) * | 2007-03-23 | 2008-10-02 | Amgen Inc. | Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer |
| JP5527761B2 (ja) * | 2007-03-23 | 2014-06-25 | アムジエン・インコーポレーテツド | 複素環化合物およびそれの使用 |
| ES2587738T3 (es) * | 2007-12-21 | 2016-10-26 | Ucb Biopharma Sprl | Derivados de quinoxalina y quinolina como inhibidores de quinasa |
| GB0819593D0 (en) | 2008-10-24 | 2008-12-03 | Ucb Pharma Sa | Therapeutic agents |
| ES2520345T3 (es) * | 2009-11-12 | 2014-11-11 | Ucb Pharma, S.A. | Derivados de quinolina y quinoxalina en calidad de inhibidores de quinasa |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
-
2011
- 2011-08-30 AR ARP110103154A patent/AR082799A1/es active IP Right Grant
- 2011-09-02 ME MEP-2015-120A patent/ME02203B/me unknown
- 2011-09-02 CA CA2808959A patent/CA2808959C/en active Active
- 2011-09-02 MY MYPI2013000767A patent/MY162396A/en unknown
- 2011-09-02 MX MX2013002529A patent/MX2013002529A/es active IP Right Grant
- 2011-09-02 RS RS20150538A patent/RS54202B1/en unknown
- 2011-09-02 WO PCT/GB2011/051647 patent/WO2012032334A1/en active Application Filing
- 2011-09-02 AU AU2011300521A patent/AU2011300521B2/en active Active
- 2011-09-02 KR KR1020137008975A patent/KR101880280B1/ko active IP Right Grant
- 2011-09-02 JP JP2013527681A patent/JP5820882B2/ja active Active
- 2011-09-02 US US13/821,294 patent/US9029392B2/en active Active
- 2011-09-02 CN CN201180049091.2A patent/CN103153996B/zh active Active
- 2011-09-02 SI SI201130542T patent/SI2614061T1/sl unknown
- 2011-09-02 PT PT117554238T patent/PT2614061E/pt unknown
- 2011-09-02 NZ NZ607966A patent/NZ607966A/en unknown
- 2011-09-02 HU HUE11755423A patent/HUE025223T2/en unknown
- 2011-09-02 EA EA201300317A patent/EA024162B1/ru not_active IP Right Cessation
- 2011-09-02 BR BR112013004750-0A patent/BR112013004750B1/pt active IP Right Grant
- 2011-09-02 MA MA35807A patent/MA34600B1/fr unknown
- 2011-09-02 DK DK11755423.8T patent/DK2614061T3/en active
- 2011-09-02 SG SG2013012794A patent/SG187924A1/en unknown
- 2011-09-02 PL PL11755423T patent/PL2614061T3/pl unknown
- 2011-09-02 ES ES11755423.8T patent/ES2544289T3/es active Active
- 2011-09-02 EP EP20110755423 patent/EP2614061B1/en active Active
- 2011-09-06 TW TW100132061A patent/TWI510489B/zh active
-
2013
- 2013-02-21 IL IL224841A patent/IL224841A/en active IP Right Grant
- 2013-03-01 CL CL2013000603A patent/CL2013000603A1/es unknown
- 2013-03-07 ZA ZA2013/01751A patent/ZA201301751B/en unknown
- 2013-03-21 CO CO13056775A patent/CO6680717A2/es active IP Right Grant
- 2013-07-30 HK HK13108926.7A patent/HK1181754A1/xx unknown
-
2015
- 2015-08-11 SM SM201500195T patent/SMT201500195B/xx unknown
- 2015-08-13 HR HRP20150868TT patent/HRP20150868T1/hr unknown
- 2015-08-18 CY CY20151100718T patent/CY1116734T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116734T1 (el) | Παραγωγα κινολινης και κινοξαλινης ως αναστολεις της κινασης | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| UY39630A (es) | Inhibidores de bromodominios | |
| CY1119892T1 (el) | Φορεις και αλληλουχιες για την αγωγη ασθενειων | |
| CY1125279T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
| CY1122168T1 (el) | Φαρμακοτεχνικες μορφες παραγωγων δεσιταβινης | |
| EA201991555A1 (ru) | Композиции и способы усиления или увеличения продукции ifn i типа | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CY1119518T1 (el) | Τροποποιημενα αντιγονα φυματιωσης | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| CY1121929T1 (el) | Ενωσεις δεσμευσης νηε3 και μεθοδοι για την αναστολη μεταφορας φωσφορικου | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| EA201201400A1 (ru) | Композиции и способы лечения аутоиммунных и других заболеваний | |
| MX2015012933A (es) | Micrordenamiento para suministro de agente terapeutico y metodos de uso. | |
| DK3377495T3 (da) | 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinon-derivativer som phosphodiesterasehæmmere og anvendelser deraf | |
| CY1120355T1 (el) | Αναστολεις toy iap | |
| EA201301018A1 (ru) | Режимы дозирования для лечения болезни фабри | |
| AR081678A1 (es) | Metodos y composiciones para administracion intratecal de arisulfatasa a | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| DK3303592T3 (da) | Gen for hanlig sterilitet hos hvede, wms, og den støvknapsspecifikke ekspressionspromotor samt anvendelser deraf | |
| DOP2009000215A (es) | Administracion semanal de inhibidores de peptidasa de pipeptidilo | |
| WO2012119070A3 (en) | Silicone-based ophthalmic formulations | |
| CY1118968T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
| WO2013040251A8 (en) | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |